The Frontier Drug INT230-6 Has Shown Promising Therapeutic Results In Soft Tissue Sarcoma!
St. Marianna University School of Medicine
US National Children's Hospital
Newly Approved Targeted Drug Makes 79% Of Patients' Tumours Disappear Altogether, This Type Of Blood Tumour Is Saved!
Cabozantinib In Combination With Atelizumab Works Well For Advanced Head And Neck Cancer
FDA Grants Orphan Drug Status To Two New Therapies In a Row, And These Two Groups Of Patients Are Expected To Benefit!
